Hepatitis/MASH

Hexavalent vaccine protects against diphtheria, tetanus, pertussis, polio, invasive disease caused by Haemophilus influenzae type b, and hepatitis B.

The FDA is reviewing a Biologics License Application for the first pediatric combination vaccine designed to help protect against 6 diseases.

SVR12 rates significantly higher in patients treated with daclatasvir/peginterferon alfa/ribavirin combination.

Provides use, cost forecast based on testing, future treatment rates.

Harvoni is comprised of sofosbuvir, a previously approved HCV drug marketed under the brand name Sovaldi, and a new drug called ledipasvir.

The drugmaker will no longer pursue FDA approval of its dual daclatasvir and asunaprevir treatment for patients with hepatitis C virus genotype 1b.

Researchers from Saint Louis University Medical Center will test the safety and efficacy of sofosbuvir and ribavirin in children with hepatitis C.

Investigators aim to reduce side effects of therapy with sofosbuvir in children with hepatitis C.

Among HIV-positive patients, concurrent use of medications is associated with nonadherence to antiretroviral therapy.

Much higher rate of patients in real world discontinuing high priced treatment than during clinical studies.

Results of a phase 3 trial demonstrate the effectiveness of simeprevir in combination with ribavirin and peginterferon as a treatment for patients coinfected with HIV and HCV.

Data indicates that a simeprevir-based therapy is efficacious in patients with HIV-1/HCV genotype 1 coinfection.

A recent study published in the journal Hepatology indicates that as many as 11% of baby boomers had a positive test result for presence of anti-HCV antibodies.

Study finds HIV suppression reduces hepatitis C viral replication over time.

New drugs to treat hepatitis C herald a new era of higher cure rates, but with these new treatment options comes an increased need for patient support and adherence counseling.

With the recent approval of new hepatitis C treatments, payers are increasingly concerned with controlling costs in this category through policies that may affect treatment decisions.